

# ***Withania somnifera*** **(Ashwagandha): A Comprehensive Monograph on Pharmacology, Efficacy, and Clinical Safety**

## **1\. An Introduction to *Withania somnifera* as a Premier Adaptogen**

### **1.1 Botanical and Ethnopharmacological Context**

*Withania somnifera* (L.) Dunal is a perennial woody plant belonging to the Solanaceae, or nightshade, family.1 It is a greyish, branched shrub that reaches approximately 150 cm in height and is characterized by its extended tuberous roots.1 Commonly known as Ashwagandha, Indian ginseng, or Indian winter cherry, this plant is one of the most essential therapeutic agents in the Indian subcontinent.2  
The name "Ashwagandha" is derived from Sanskrit, combining "ashwa" (horse) and "gandha" (fragrance), a reference to both the distinct odor of the fresh root and the traditional belief that its consumption imparts the vigor and power of a horse.3 This belief is central to its ethnopharmacological identity. For over 3,000 years, *W. somnifera* has been a cornerstone of Ayurvedic medicine.2 In this system, it is classified as a "Rasayana" (rejuvenator), a prized class of herbs esteemed for promoting general health, strengthening the nervous system, enhancing longevity, and improving overall well-being.3  
Historically, the root of the plant has been used as a general tonic, aphrodisiac, narcotic, and diuretic.3 Its primary traditional applications—for treating anxiety, insomnia, chronic stress, impotence, and male infertility—align directly with the major avenues of modern clinical investigation.5

### **1.2 Key Bioactive Constituents**

*W. somnifera* is a complex phytochemical entity, with research identifying over 50 bioactive constituents.8 This chemical diversity, which includes alkaloids, flavonoids, tannins, saponins, and glycosides, is thought to be responsible for the plant's wide-ranging therapeutic indications.8  
The principal pharmacological activity, however, is attributed to a group of C-28 steroidal lactones known as **withanolides**.9 These compounds are characteristic of the Solanaceae family and are the primary drivers of the plant's biological effects.10 The most extensively studied and biologically active withanolides include **Withaferin A**, **Withanolide A**, and **Withanone**.1 Alongside these are the glycowithanolides, such as **sitoindosides** (specifically VII-X), which are noted for their antioxidant and anti-stress properties.9 This unique constellation of active compounds is the basis for the anti-inflammatory, antioxidant, immunomodulatory, anti-stress, and anti-cancer properties documented in preclinical and clinical research.1  
A critical pharmacological distinction exists between the plant parts. Traditional Ayurvedic practice and many modern clinical trials exclusively use the *root* of the plant.3 However, some of the most potent and pharmacologically active constituents, particularly Withaferin A, are found in high concentrations in the *leaves*.16 This divergence is fundamental. A "root-only" extract (e.g., KSM-66) will possess a different phytochemical and toxicological profile than a "root-and-leaf" extract (e.g., Sensoril).14 This distinction is a crucial variable for interpreting efficacy and safety, particularly as it relates to the widespread market adulteration with undeclared leaf material.18  
The presence of dozens of phytochemicals means *W. somnifera* functions as a synergistic mixture, not a single-molecule agent.8 Different extraction methods (e.g., water versus alcohol) yield mechanistically distinct extracts, which in turn produce different therapeutic outcomes.8 This chemical complexity explains the heterogeneity observed in clinical trials 19 and underscores the necessity of evaluating the *entire extract*—not just one or two withanolide markers—as the active pharmaceutical ingredient.

## **2\. Core Pharmacological Mechanisms of Action**

The wide array of clinical effects attributed to *W. somnifera* is supported by its ability to modulate multiple, interconnected physiological pathways. It does not function as a "magic bullet" for a single receptor but rather as a systemic regulator that restores homeostasis.

### **2.1 Neuro-Endocrine and Stress Response (The Adaptogenic Core)**

The primary mechanism underpinning Ashwagandha's "adaptogenic" classification is its profound effect on the neuro-endocrine stress response. A systematic review of various supplements concluded that Ashwagandha demonstrates the "most profound effect on the hypothalamic-pituitary-adrenal (HPA) axis".20  
In states of chronic stress, the HPA axis becomes dysregulated, leading to excessive and prolonged secretion of cortisol. *W. somnifera* appears to buffer this response, modulating the axis and reducing pathological cortisol secretion.21 Preclinical studies confirm that its constituents can reduce the activation of both the HPA and the sympathetic-adrenal-medullary (SAM) axes.14 This mechanism provides a direct biological explanation for the clinical findings (detailed in Section 3.1) of significantly reduced serum cortisol levels in chronically stressed human subjects.

### **2.2 Neurological Pathways (Anxiolytic and Sedative Effects)**

The anxiolytic and sleep-promoting effects of Ashwagandha are strongly linked to its modulation of the gamma-aminobutyric acid (GABA) system, the body's primary inhibitory neurotransmitter network. Research provides "direct evidence for GABAergic activity," showing that *W. somnifera* constituents can modulate mammalian ionotropic GABAA and GABAρ receptors.3 This action is believed to be the source of its "sleep-inducing potential".20  
These mechanisms are not isolated. A critical synergistic loop exists: GABAergic activation has been shown to *decrease* HPA axis activation.14 This suggests that Ashwagandha's anxiolytic effects (via GABA) and its anti-stress effects (via HPA modulation) are mutually reinforcing. This multi-target engagement—dampening stress-hormone output while simultaneously enhancing inhibitory neurotransmission—is the scientific basis for its adaptogenic classification.

### **2.3 Anti-Inflammatory and Antioxidant Activity**

*W. somnifera* exhibits potent anti-inflammatory action by intervening in key signaling cascades. A primary mechanism is the robust inhibition of the **NF-κB (Nuclear Factor Kappa B)** pathway, a master regulator of the inflammatory response.3 Withaferin A, in particular, has been shown to prevent the phosphorylation of Iκ-β, which physically blocks NF-κB translocation to the nucleus and prevents the transcription of pro-inflammatory genes.13  
This inhibition is broad-spectrum, also targeting other inflammatory pathways including P38, JNK/SAPK, and MAPK, and reducing downstream markers such as TNF-α, IL-8, and COX-2.3  
Its antioxidant effects are two-fold. First, constituents like withanolides and sitoindosides act as direct scavengers of free radicals (Reactive Oxygen Species, ROS).1 Second, and perhaps more importantly, they function as restorative agents, restoring levels of endogenous antioxidant enzymes (e.g., Superoxide Dismutase, Catalase, Glutathione Peroxidase) that are depleted during periods of high oxidative stress.13

### **2.4 Neuroprotective and Cognitive Mechanisms**

The neuroprotective effects of Ashwagandha are multifaceted, arising from its anti-inflammatory, antioxidant, and anti-stress activities, as well as more direct mechanisms.26  
A unique mechanism identified in transgenic mouse models of Alzheimer's disease involves the clearance of amyloid-β (Aβ). A *W. somnifera* root extract was found to increase the expression of the LDL receptor-related protein (LRP1) in the *liver*. This peripheral action enhanced the systemic clearance of Aβ from the bloodstream, thereby reducing the Aβ burden in the brain and reversing associated behavioral deficits.3  
Other models demonstrate that its constituents protect against cognitive dysfunction by upregulating NMDA receptor activity, which is crucial for memory formation 26, and by promoting neurogenesis through increased levels of brain-derived neurotrophic factor (BDNF) in the hippocampus.27

### **2.5 Oncological Mechanisms (Primarily Pre-Clinical)**

A significant body of *in vitro* and *in vivo* research has focused on the anti-cancer potential of Ashwagandha, with Withaferin A (WA) as the primary agent of interest.9 WA appears to be a potent, multi-target agent that induces apoptotic (programmed) cell death in cancer cell lines via several pathways:

* **STAT-3 Pathway:** It induces dose-dependent apoptosis by down-regulating the STAT-3 pathway.13  
* **ER Stress:** It causes endoplasmic reticulum (ER) stress, which upregulates the pro-apoptotic transcription factor CHOP.13  
* **Caspase Activation:** It directly activates the caspase cascade and promotes PARP-1 cleavage, which are hallmarks of apoptosis.13  
* **Proteasome Inhibition:** It inhibits the proteasome, a mechanism used by several conventional chemotherapy drugs.13

However, the pharmacological profile of Withaferin A is not uniformly positive. "Conflictual reports" exist.13 In models using *healthy* (non-cancerous) rabbit articular chondrocytes, WA was found to *induce* inflammatory responses, including COX-2 upregulation, and cause a "marked exacerbation" of intracellular ROS.13  
This contradictory finding is of profound pharmacological significance. It suggests that the very mechanisms making WA a potent anti-cancer agent (e.g., induction of ER stress, ROS generation, and apoptosis) 13 could be the same mechanisms responsible for its toxicity in healthy cells. This preclinical conflict is a plausible explanation for the hepatotoxicity observed in human case reports (detailed in Section 4.2), and it strongly supports the traditional use of synergistic, whole-root extracts, which may buffer the cytotoxic effects of any single, isolated compound.

## **3\. Clinical Evidence Review: Efficacy in Human Trials**

This section synthesizes the evidence for *W. somnifera*'s efficacy from human clinical trials, with a strong prioritization of data from recent systematic reviews (SR) and meta-analyses (MA).

### **3.1 Stress, Anxiety, and Cortisol Regulation**

The strongest evidence for Ashwagandha's clinical use is in the management of stress and anxiety. A 2024 systematic review and meta-analysis incorporating nine randomized controlled trials (RCTs) with 558 patients found significant beneficial effects compared to placebo.28  
The quantitative outcomes from this meta-analysis demonstrate clinically meaningful reductions in subjective stress and anxiety:

* **Perceived Stress Scale (PSS):** Mean Difference (MD) \= \-4.72 (95% CI: \-8.45 to \-0.99).28  
* **Hamilton Anxiety Scale (HAM-A):** MD \= \-2.19 (95% CI: \-3.83 to \-0.55).28

This subjective improvement is mirrored by a significant change in the primary objective biomarker of stress. The same 2024 meta-analysis found a statistically significant reduction in serum cortisol levels 23:

* **Serum Cortisol:** MD \= \-2.58 (95% CI: \-4.99 to \-0.16).28

Effective doses in the reviewed trials ranged from 125 mg/day to 1000 mg/day.20 It should be noted that an earlier 2014 systematic review (5 trials) reached similar positive conclusions but cautioned that all included studies exhibited an "unclear or high risk of bias" and high heterogeneity, which prevented a meta-analysis at that time.15 The more recent MAs suggest that as trial quality has improved, the positive effect has been confirmed.

### **3.2 Sleep and Insomnia**

A 2021 systematic review and meta-analysis (5 RCTs, n=400 participants) evaluated Ashwagandha extract for sleep.30 The analysis found a "small but significant effect on overall sleep" compared to placebo.31

* **Overall Sleep:** Standardized Mean Difference (SMD) \= \-0.59 (95% CI: \-0.75 to \-0.42).30

The most critical findings from this meta-analysis come from its subgroup analyses, which reveal that the effect is not uniform. The benefits of Ashwagandha on sleep are *most prominent* under specific conditions 20:

* **Population:** The effect was stronger in adults diagnosed with **insomnia** (SMD \-0.84) compared to healthy adults (SMD \-0.63).31  
* **Dosage:** The effect was greater at a dosage of **$\\ge$600 mg/day** (SMD \-0.69) versus \<600 mg/day (SMD \-0.44).31  
* **Duration:** The effect was more profound with a treatment duration of **$\\ge$8 weeks**.20

These findings demonstrate a clear restorative pattern: the herb is most effective in those with a diagnosed sleep disorder. Trials also noted a significant secondary benefit of improved "mental alertness on rising," suggesting a restorative sleep, not a "hangover" sedative effect.30

### **3.3 Physical and Athletic Performance (Ergogenic Effects)**

Multiple systematic reviews and meta-analyses have assessed *W. somnifera* as a potential ergogenic aid, concluding that it significantly enhances physical performance in both healthy individuals and athletes.16  
The most consistently reported outcome is a significant improvement in cardiorespiratory endurance, measured by maximal oxygen uptake (VO2max):

* A meta-analysis of 5 studies (n=162) found a mean difference of **MD \= 3.00 mL/kg/min** (95% CI: 0.18 to 5.82).37  
* A separate 2024 meta-analysis (8 studies) focusing on athletes found an even larger improvement of **MD \= 4.09 ml/min/kg** (95% CI: 2.55 to 5.63).38

Evidence also strongly supports its utility in resistance training. Clinical trial regimens, typically 300-500 mg twice daily for 8-12 weeks, have been associated with 38:

* Significant increases in muscle strength (e.g., bench-press) and arm muscle size.16  
* Enhanced recovery and a "substantial reduction in exercise-induced muscle damage," objectively measured by the stabilization of serum creatine kinase levels post-exercise.38

### **3.4 Male Reproductive Health and Testosterone**

An evidence-based systematic review and meta-analysis on male infertility found "promising" though "limited" data, primarily due to a small number of eligible studies.3  
However, the quantitative results from the included RCT in oligospermic males are striking. After 90 days of treatment, the *W. somnifera* group showed 7:

* **Sperm Concentration:** \+167% increase  
* **Semen Volume:** \+59% increase  
* **Sperm Motility:** \+57% increase

A meta-analysis of observational studies included in the same review supported this, finding a mean difference of **\+13.57 million/ml** for sperm concentration and **\+8.50%** for sperm motility.7  
These fertility improvements are linked to a hormonal effect. A 2021 systematic review on herbal extracts and testosterone in men identified Ashwagandha (root and root/leaf extracts) as having the **strongest positive effects** on testosterone concentrations among all herbs reviewed.43 The infertility RCT found a **\+17%** increase in serum testosterone 7, while another SR/MA reported a pooled average increase of **145.7 ng/dL** in male participants.44

### **3.5 Cognitive Function and Neuroprotection**

The evidence for cognitive enhancement is less robust than for stress or sleep, consisting of RCTs in specific populations rather than large meta-analyses of healthy adults.3 One systematic review noted that the existing low-quality studies and heterogeneity limited the impact of its findings.46  
The most compelling data emerges from trials on patients with existing cognitive deficits, reinforcing its restorative, adaptogenic pattern.

* **Bipolar Disorder:** An 8-week RCT (500 mg/day) used as an adjunctive therapy demonstrated improvements in auditory-verbal working memory, reaction time, and social cognition.46  
* **Mild Cognitive Impairment (MCI):** An 8-week RCT (300 mg twice daily) showed significant improvements in immediate and general memory, executive function, sustained attention, and information-processing speed compared to placebo.46  
* **Healthy, Stressed Adults:** A study using a 300 mg sustained-release capsule also found improvements in memory and focus.49

### **3.6 Adjunctive Therapeutic Potential**

Preliminary evidence suggests *W. somnifera* may have a role as an adjunctive (add-on) therapy in severe psychiatric disorders.51 An RCT found 600 mg/day was beneficial as an adjunctive treatment for schizophrenia.4 Another study in patients with Generalized Anxiety Disorder (GAD) noted that the extract "could potentially support SSRI therapy" when used concurrently.3  
Despite the strong placebo-controlled data across these indications, there is a significant and conspicuous absence of head-to-head trials comparing Ashwagandha to standard-of-care (SoC) pharmaceuticals. Searches for direct comparisons to benzodiazepines (e.g., Lorazepam) or SSRIs (e.g., Sertraline) do not yield results for Ashwagandha, though such trials exist for other herbs like Kava and Lavender.52 This evidence gap is why a World Federation of Societies of Biological Psychiatry (WFSBP) taskforce, while provisionally recommending Ashwagandha for GAD, noted they "cannot provide a stronger recommendation without more data".32  
Based on the current evidence, Ashwagandha cannot be recommended as a *replacement* for SoC in diagnosed GAD, but its role as an adjunctive therapy or as a primary therapy for mild-to-moderate or sub-clinical stress and anxiety is well-supported.  
**Table 1: Summary of Clinical Efficacy from Meta-Analyses**

| Indication | Key Outcome Measure | No. of Studies (Participants) | Quantitative Result (MD or SMD) | 95% Confidence Interval | Source(s) |
| :---- | :---- | :---- | :---- | :---- | :---- |
| **Stress** | Perceived Stress Scale (PSS) | 9 RCTs (n=558) | MD \= \-4.72 | \[-8.45 to \-0.99\] | 28 |
| **Anxiety** | Hamilton Anxiety Scale (HAM-A) | 9 RCTs (n=558) | MD \= \-2.19 | \[-3.83 to \-0.55\] | 28 |
| **Stress** | Serum Cortisol | 9 RCTs (n=558) | MD \= \-2.58 | \[-4.99 to \-0.16\] | 28 |
| **Sleep** | Overall Sleep Quality | 5 RCTs (n=400) | SMD \= \-0.59 | \[-0.75 to \-0.42\] | 30 |
| **Performance** | VO2max (Healthy/Athletes) | 5 Studies (n=162) | MD \= 3.00 mL/kg/min | \[0.18 to 5.82\] | 37 |
| **Performance** | VO2max (Athletes) | 8 Studies | MD \= 4.09 mL/kg/min | \[2.55 to 5.63\] | \[38\] |
| **Male Infertility** | Sperm Concentration (RCT) | 1 RCT | \+167% (vs. baseline) | N/A | 7 |
| **Male Infertility** | Sperm Concentration (Obs. MA) | (Meta-analysis) | MD \= 13.57 million/ml | \[11.12 to 16.01\] | 7 |

*MD \= Mean Difference; SMD \= Standardized Mean Difference.*

## **4\. Safety, Toxicology, and Risk Assessment**

A critical analysis of *W. somnifera* reveals a significant contradiction between the safety profile reported in controlled clinical trials and the emerging, serious risks identified in post-marketing surveillance.

### **4.1 General Safety and Adverse Events (From Clinical Trials)**

Across more than 30 human trials, Ashwagandha root preparations are consistently described as "non-toxic," "safe," and "well-tolerated".4 When adverse events are reported, they are typically mild and transient, including gastrointestinal symptoms (nausea, diarrhea, epigastric pain) and neurological effects (somnolence).4 The major meta-analyses for sleep and anxiety explicitly report "no serious side effects" or "no serious adverse events".4  
This benign profile, however, is a direct artifact of the clinical trial setting. RCTs are typically short-term (8-12 weeks) and enroll healthy adults, while *explicitly screening out* individuals with pre-existing conditions, such as chronic liver disease. As the following sections demonstrate, this "safety" data is not generalizable to a broader, real-world population that includes individuals with undiagnosed or underlying health conditions.

### **4.2 Significant Risk Profile: Drug-Induced Liver Injury (DILI)**

In stark contrast to the trial data, an "increasing number of cases" of clinically apparent hepatotoxicity are being reported in the literature.54 This has led the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) LiverTox database to assign Ashwagandha a **Likelihood Score: B (Likely cause of clinically apparent liver injury)**.55  
The clinical presentation of Ashwagandha-HILI, synthesized from case reports, is as follows 55:

* **Onset:** Typically occurs **2 to 12 weeks** after initiating the supplement.  
* **Phenotype:** The injury is most commonly a **cholestatic or mixed pattern**, characterized by severe **jaundice** (elevated bilirubin) and **pruritus (itching)**. Some cases may present initially as hepatocellular.54  
* **Symptoms:** Nausea, lethargy, dark urine, jaundice, and pruritus are the most common presenting symptoms.56  
* **Causality:** This is believed to be an intrinsic hepatotoxicity from *W. somnifera* itself, not a result of contamination, as commercial products in several reported cases were tested and "found to have ashwagandha without other contaminants".55

The clinical outcome of the DILI is highly dependent on the patient's underlying health.

* **In Healthy Adults:** Most cases are mild-to-moderate and **self-limited**. Liver enzymes and bilirubin typically normalize within **1 to 4 months** of discontinuing the herb.54  
* **In At-Risk Patients:** This is the most critical safety finding. In patients with **pre-existing chronic liver disease (CLD)**—such as Non-Alcoholic Fatty Liver Disease (NAFLD), NASH, or cirrhosis—Ashwagandha-HILI is far more dangerous. It can trigger **acute-on-chronic liver failure (ACLF)**, a syndrome with a **high mortality rate**.55  
* A 2022 case series from India (8 patients) starkly illustrates this risk: 5 of the 8 patients had underlying CLD. Of those 5, 3 progressed to ACLF, and **all 3 died**.57

### **4.3 Contraindications and Specific Population Warnings**

The second major safety concern is Ashwagandha's direct, pharmacological effect on the thyroid. This effect is not a "side effect" but a primary action; whether it is a "benefit" or a "risk" depends entirely on the patient's baseline thyroid status.

* **As a "Benefit" (Hypothyroidism):** An 8-week RCT (n=50) in patients diagnosed with *subclinical hypothyroidism* (elevated TSH) found that 600 mg/day of Ashwagandha root extract "effectively normalized" their thyroid indices.4 Compared to placebo, the treatment group showed a significant:  
  * **Increase** in serum T3 (by 41.5%)  
  * **Increase** in serum T4 (by 19.6%)  
  * **Decrease** in serum TSH 61  
* **As a "Risk" (Hyperthyroidism):** This same thyroid-stimulating activity 62 creates a clear and present danger for individuals who are euthyroid (normal function) or who are already taking thyroid-stimulating medication. Multiple case reports now link Ashwagandha consumption to **drug-induced thyrotoxicosis** (painless thyroiditis).60  
  * **Case 1:** A 73-year-old female using Ashwagandha for 2 years presented with supraventricular tachycardia and significantly low TSH (indicating a hyperthyroid state).66  
  * **Case 2:** A 47-year-old male bodybuilder developed thyrotoxicosis after 2 months of use.67  
  * In all cases, symptoms and thyroid markers improved upon cessation of the herb.64

This evidence establishes a firm contraindication for Ashwagandha use in patients with hyperthyroidism and necessitates extreme caution and monitoring in any patient taking thyroid medication (e.g., Levothyroxine), as the additive effect could easily push them into a state of thyrotoxicosis.  
**Table 2: Summary of Significant Adverse Reactions and Risk Profiles**

| Risk Profile | Clinical Presentation / Phenotype | Onset / Duration | Key Risk Factors | Clinical Outcome | Source(s) |
| :---- | :---- | :---- | :---- | :---- | :---- |
| **Drug-Induced Liver Injury (DILI)** | Cholestatic or Mixed Injury. Jaundice, Pruritus, Nausea, Elevated LFTs/Bilirubin. | **Onset:** 2 \- 12 weeks **Duration:** 1 \- 4 months (if self-limiting) | **Pre-existing Chronic Liver Disease** (NAFLD, NASH, Cirrhosis). | **LiverTox Score B (Likely)**. Self-limiting in healthy adults. **High mortality** via Acute-on-Chronic Liver Failure (ACLF) in CLD patients. | \[54, 55, 57\] |
| **Thyrotoxicosis** | Painless Thyroiditis. Low TSH, elevated T3/T4. Symptoms of hyperthyroidism (tachycardia, anxiety). | **Onset:** 2 months \- 2 years | Euthyroid (normal) status; Concomitant use with thyroid medication; Pre-existing hyperthyroidism. | Symptoms and thyroid markers normalize upon discontinuation of the herb. | \[64, 65, 66, 67\] |

## **5\. Pharmacokinetics and Herb-Drug Interaction Potential**

The translation of Ashwagandha from a traditional remedy to a modern supplement is complicated by a significant lack of pharmacokinetic (PK) data and a clear potential for drug interactions.

### **5.1 Human Pharmacokinetics (PK) and Bioavailability**

The body of human PK data for *W. somnifera* is exceptionally limited. A 2024 review noted only four human PK studies compared to fifteen in animals, highlighting a major research gap.68 This scarcity makes it difficult to establish reliable dosing, absorption, and clearance parameters.12  
The available human data demonstrates that the PK parameters are *not* dose-proportional and are *wildly dependent* on the proprietary formulation, likely due to different extraction methods, excipients, and bioavailability-enhancing technologies.

* **Case 1:** A study comparing two extracts (WS-35 vs. WS-2.5) that were *normalized to the same 185 mg total withanolide dose* found that the WS-35 extract produced a **5.62-fold higher Cmax** (peak concentration) and a **5.18-fold higher half-life**.70  
* **Case 2:** A 125 mg dose of a novel formulation (ZEN 1.5) was found to have **2.1-fold higher bioavailability** (Cmax and AUC) than a 600 mg dose of a standard extract (ASH 5).71

These findings demonstrate that the *formulation technology* is a more significant determinant of bioavailability than the raw milligram dosage. This variability is a massive confounder that helps explain the "heterogeneity" reported in clinical meta-analyses.19 Bioavailability is further complicated by the fact that many active withanolides exist as glycosides (e.g., withanoside IV), which must be hydrolyzed by gut microflora into their aglycone (active) forms before or after absorption, adding a significant layer of inter-patient variability.72

### **5.2 Cytochrome P450 (CYP) and Transporter Interactions**

As a complex phytochemical mixture, *W. somnifera* has a significant, and often underestimated, potential for pharmacokinetic herb-drug interactions. These interactions are primarily mediated by the modulation of Cytochrome P450 (CYP) metabolic enzymes and the P-glycoprotein (P-gp) efflux transporter.73  
The *in vitro* data on this topic is a mire of contradictions.

* **"No/Weak Inhibition" Data:** Several studies using aqueous root extracts (WSE) report "no significant inhibitory activities" on CYP3A4 75, "no inhibitory effect" on CYP3A4, CYP2C8, or CYP2D6 76, and "no, or only a weak impact" on P450 induction.77  
* **"Strong Inhibition" Data:** In stark contrast, other reviews state that Ashwagandha "inhibits also CYP3A4 and CYP2D6".79 Furthermore, *in vitro* studies on the isolated constituent **Withaferin A** (which is more lipophilic and less present in simple aqueous extracts) show it is both a **"CYP3A4 substrate"** and a **"strong P-glycoprotein-inhibitor"**.80

This conflict is likely explained by the *type* of extract used—water-based extracts have a different constituent profile and thus a different interaction risk than full-spectrum or alcohol extracts.  
The most reliable and clinically relevant data comes from a retrospective chart review of *actual adverse events* in patients taking Ashwagandha concurrently with antidepressants.73 This *in vivo* human data cuts through the *in vitro* noise and confirms that clinically significant interactions do occur.

* **Ashwagandha \+ Sertraline (SSRI):** Resulted in "severe diarrhea requiring hospitalization." The proposed mechanism was **P-gp inhibition** by Ashwagandha, which increased the concentration of Sertraline (a P-gp substrate).73  
* **Ashwagandha \+ Escitalopram (SSRI):** Resulted in "myalgia." The proposed mechanism was **inhibition of P-gp, CYP3A4, and CYP2D6** by Ashwagandha, increasing the concentration of Escitalopram (a substrate for all three).73  
* **Ashwagandha \+ Reboxetine (SNRI):** Resulted in "testicle pain, ejaculatory dysfunctions." The proposed mechanism was **inhibition of CYP3A4 and CYP2D6** by Ashwagandha, increasing the concentration of Reboxetine (metabolized by both).73

This evidence confirms that the interaction potential is real and clinically relevant, particularly via P-gp inhibition, posing a significant risk for patients taking common psychiatric medications.  
**Table 3: Clinically Relevant Herb-Drug Interaction Profile**

| Target (Enzyme/Transporter) | In Vitro / In Vivo Effect | Example Substrate Drugs | Reported Adverse Interaction (Clinical) | Source(s) |
| :---- | :---- | :---- | :---- | :---- |
| **CYP3A4** | **Conflicting *in vitro*** (No/Weak to Inhibition); **Clinical *In Vivo* Interaction**. | Escitalopram, Reboxetine, Trazodone | Myalgia (with Escitalopram); Psoriasis relapse (with Trazodone) | \[73, 75, 79, 80\] |
| **CYP2D6** | **Conflicting *in vitro*** (No/Weak to Inhibition); **Clinical *In Vivo* Interaction**. | Escitalopram, Reboxetine, Venlafaxine | Ejaculatory dysfunction (with Reboxetine); Hyponatremia (with Venlafaxine) | \[73, 76, 79\] |
| **P-glycoprotein (P-gp)** | **Strong Inhibition** (Withaferin A); **Clinical *In Vivo* Interaction**. | Sertraline, Escitalopram, Paroxetine | Severe diarrhea (with Sertraline); Myalgia (with Escitalopram) | \[73, 80, 82\] |

## **6\. Market Analysis: Standardization, Quality, and Adulteration**

The single greatest challenge in translating the positive clinical data on *W. somnifera* to public use is the catastrophic failure of quality control in the dietary supplement market.

### **6.1 Dosing and Standardized Extracts**

The clinical trials that have demonstrated efficacy (Section 3\) almost universally use high-quality, standardized extracts, not simple raw powder.

* **Clinical Dosing:** Efficacious daily doses typically range from **300 mg to 1000 mg** of a standardized extract.15 A common protocol is **600 mg/day** (e.g., 300 mg twice daily).14  
* **Standardization:** Quality products are standardized to a specific percentage of **withanolides**, typically between 2.5% and 10%.25  
* **Proprietary Extracts:** Two branded extracts dominate the clinical literature:  
  1. **KSM-66:** A high-concentration, **"root-only"** extract created using water-based, "green chemistry" extraction.9  
  2. **Sensoril:** A **"root and leaf"** extract, also aqueous-based.14  
* **Analytical Methods:** The United States Pharmacopeia (USP) and other bodies provide validated High-Performance Liquid Chromatography (HPLC) and High-Performance Thin-Layer Chromatography (HPTLC) methods for quantifying specific withanolides (e.g., Withaferin A, Withanoside IV) to aid in quality control and authentication.86

### **6.2 The Crisis of Quality Control and Adulteration**

A "Great Disconnect" exists between the high-quality products used in RCTs and the products available to consumers. The positive clinical data may be entirely inapplicable to the average off-the-shelf product.

* **Widespread Adulteration:** The American Botanical Council's (ABC) Botanical Adulterants Prevention Program (BAPP) has issued a specific bulletin on Ashwagandha.93 The primary economic adulteration is the undeclared addition of cheaper **leaves and stems** to products labeled "root-only".18 This is particularly insidious because simple analytical tests for "total withanolides" are *insufficient* to detect this fraud, as leaves also contain withanolides.18 This is not just an economic issue but a pharmacological one, as the leaf contains a different profile of compounds (e.g., higher Withaferin A) and thus a different safety profile.  
* **Failure to Meet Label Claims:** The quality control failure is severe and widespread.  
  * A 2024 analysis of 10 dietary supplements labeled as "Ashwagandha root extract" found that **100% (10 out of 10\) failed** to fulfill the manufacturers' claims.96  
  * These products, which claimed a 5% median withanolide concentration, were found by quantitative HPLC to contain only **\~0.15% withanolides**—a potency **33 times lower** than advertised.96  
  * Microscopic analysis confirmed that the capsules did not contain "extract" at all, but merely **"pulverized raw root,"** which was mislabeled.96  
  * This is corroborated by independent lab testing from ConsumerLab.com, which found that in one 2024 review, only **38%** of Ashwagandha products passed quality and labeling tests.97  
* **Contamination and Spiking Risks:**  
  * **Heavy Metals:** A systemic environmental problem. One analysis of 11 adaptogen supplements found "consistently elevated Ni (Nickel) concentrations" in all *W. somnifera* samples sourced from India, suggesting widespread contamination of the soil or water.98 Products must be tested to ensure they are below USP limits for total heavy metals (10 ppm).99  
  * **Pesticides:** These are also a known risk from agricultural inputs.99  
  * **Undeclared Pharmaceuticals:** This is an acute public health danger, particularly in the supplement categories where Ashwagandha is marketed. Products sold for "muscle building" (where Ashwagandha is used as an ergogenic aid) are frequently spiked with **synthetic steroids**; one FDA report found 89.1% of tested muscle supplements were adulterated.102 Products for "sexual enhancement" (where Ashwagandha is used for fertility) are commonly spiked with **sildenafil (Viagra)** or **tadalafil**.97 A consumer's perceived "efficacy" from an Ashwagandha-containing blend may, in fact, be from an undeclared, illegal pharmaceutical.

**Table 4: Quality & Standardization: Clinical Trial Standard vs. Consumer Market Reality**

| Parameter | Clinical Trial Standard (e.g., KSM-66) | Consumer Market Reality (Reported) | Implication | Source(s) |
| :---- | :---- | :---- | :---- | :---- |
| **Material** | Standardized "Root-Only" Extract | Undeclared "Leaves and Stems" | Different safety/efficacy profile; fraud. | \[14, 18\] |
| **Withanolide %** | Claimed & Verified (e.g., 5%) | Claimed 5%, Actual **\~0.15%** | **33x less potent.** Consumer product is sub-therapeutic. | \[83, 96\] |
| **Product Status** | Verified, concentrated extract. | Mislabeled "Pulverized Raw Root" | Consumer is not buying an extract. | 96 |
| **Contaminants** | Screened (USP standards) | Risk of Heavy Metals (Nickel), Pesticides. | Direct toxicity from contaminants. | \[98, 100\] |
| **Adulterants** | N/A (Pure) | High risk of undeclared *synthetic steroids* or *sildenafil* in "Muscle" or "Sexual" blends. | Perceived efficacy may be from illegal drugs, not the herb. | 97 |

## **7\. Synthesis, Clinical Pearls, and Future Research Directions**

### **7.1 Expert Synthesis and Recommendations**

This comprehensive analysis confirms that *Withania somnifera* is a potent, pharmacologically active botanical, not a simple panacea. The evidence, now supported by multiple systematic reviews and meta-analyses, is robust for its efficacy in several key areas:

* Reducing subjective and objective markers of **stress and anxiety**.28  
* Improving **sleep quality** and latency, particularly in individuals with insomnia.30  
* Enhancing **physical performance**, including VO2max and muscle recovery.37  
* Improving **male fertility** parameters, including sperm concentration and motility.7

This clinical efficacy is mechanistically plausible, stemming from its well-documented adaptogenic effects on the HPA axis (cortisol regulation) and its anxiolytic effects on the GABAergic system.3  
However, this strong positive profile is **severely compromised** by two critical, real-world factors that form a significant "translational gap" between the research and the consumer:

1. **A Non-Trivial Safety Risk:** There is a clear, documented risk of **Drug-Induced Liver Injury (DILI)**, which is "likely" (LiverTox Score B) and can be **fatal** in patients with pre-existing chronic liver disease.55 There is also a clear risk of inducing **thyrotoxicosis** in euthyroid or medicated patients.64  
2. **A Catastrophic Quality Failure:** The commercial market is characterized by a **widespread and severe failure of quality control**. Studies show rampant mislabeling (100% failure rate in one analysis) 96, substitution with undeclared leaf material 18, and potencies 33-fold lower than advertised.96

Therefore, while Ashwagandha is a highly promising *pharmacological agent*, it is a high-risk *consumer product*.

### **7.2 Clinical Pearls for the Informed Professional**

For clinicians, pharmacists, and researchers, the following practical points are essential:

* **Product Selection is Paramount:** Efficacy and safety are extract-dependent. Do not recommend "Ashwagandha"; recommend a *specific, high-quality product*. Prioritize brands that use a **clinically-studied, standardized extract** (e.g., KSM-66, Sensoril) and can provide **third-party verification** (e.g., USP, NSF, cGMP) for purity and potency.106  
* **Dosing and Duration:** Educate patients that efficacy is **chronic and dose-dependent**. Based on clinical trials, the target regimen is **300-600 mg/day** of a standardized extract for **at least 8-12 weeks**.25 Sub-therapeutic, "as-needed" use is unlikely to replicate trial results.  
* **Screening and Contraindications:**  
  * **Liver:** Given the risk of DILI, supplementation is **contraindicated in patients with known chronic liver disease**.57 A baseline panel of liver function tests (LFTs) should be considered before initiation in any at-risk patient (e.g., metabolic syndrome, history of alcohol abuse, known NAFLD).  
  * **Thyroid:** Given its direct thyroid-stimulating effect 61, it is **contraindicated in patients with hyperthyroidism** and must be used with extreme caution and monitoring in any patient taking thyroid medication (e.g., Levothyroxine).66  
* **Drug Interactions:**  
  * **Antidepressants:** Be highly cautious in patients on SSRIs and SNRIs. The inhibition of P-glycoprotein and CYP enzymes (CYP3A4, CYP2D6) can increase serum concentrations of these drugs, leading to toxicity (e.g., severe diarrhea with Sertraline, myalgia with Escitalopram).73  
* **Adulteration:** Be highly suspicious of multi-ingredient "proprietary blends" for muscle-building or sexual enhancement. A patient's perceived benefit may be from undeclared synthetic steroids or sildenafil, not Ashwagandha.97

### **7.3 Future Research Directions**

Significant gaps remain in the literature. The following areas represent the most urgent frontiers for future research:

* **Long-Term Safety:** The \#1 priority is the establishment of long-term safety and tolerability data (beyond 12 weeks) in diverse populations.21  
* **Toxicology:** The precise mechanism of Ashwagandha-induced DILI must be elucidated. It is unknown if this is a general withanolide effect, specific to Withaferin A, or related to a particular extract type.55  
* **Pharmacokinetics:** Robust human PK studies are a critical and "scant" gap.12 Data is needed to understand the bioavailability, metabolism, and clearance of different standardized extracts to enable reliable dosing.  
* **Comparative Efficacy:** The most significant gap in the efficacy literature is the lack of **head-to-head trials against standard-of-care** pharmaceuticals (e.g., Ashwagandha vs. Sertraline for GAD; vs. Lorazepam for acute anxiety).3  
* **New Frontiers:** Ongoing trials are exploring its use as an adjunctive therapy for schizophrenia 4 and bipolar disorder.47 Its restorative, anti-fatigue properties also make it a strong candidate for managing post-viral syndromes, and a large-scale RCT ("APRIL Trial") is underway in the UK to assess its efficacy in promoting recovery from long COVID.27

#### **Works cited**

1. Full article: A comprehensive review on the bioactivity and pharmacological attributes of Withania somnifera, accessed November 5, 2025, [https://www.tandfonline.com/doi/full/10.1080/14786419.2025.2499070?scroll=top\&needAccess=true](https://www.tandfonline.com/doi/full/10.1080/14786419.2025.2499070?scroll=top&needAccess=true)  
2. Investigating the molecular targets and therapeutic potential of Withania somnifera (Ashwagandha) in various pathophysiological conditions | Frontiers Research Topic, accessed November 5, 2025, [https://www.frontiersin.org/research-topics/37415/investigating-the-molecular-targets-and-therapeutic-potential-of-withania-somnifera-ashwagandha-in-various-pathophysiological-conditions/magazine](https://www.frontiersin.org/research-topics/37415/investigating-the-molecular-targets-and-therapeutic-potential-of-withania-somnifera-ashwagandha-in-various-pathophysiological-conditions/magazine)  
3. Ashwagandha (Withania somnifera)—Current Research on the Health-Promoting Activities: A Narrative Review \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10147008/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10147008/)  
4. Safety and clinical effectiveness of Withania Somnifera (Linn.) Dunal root in human ailments, accessed November 5, 2025, [https://pubmed.ncbi.nlm.nih.gov/32201301/](https://pubmed.ncbi.nlm.nih.gov/32201301/)  
5. Withania somnifera (L.) Dunal \- Modern perspectives of an ancient Rasayana from Ayurveda, accessed November 5, 2025, [https://pubmed.ncbi.nlm.nih.gov/32783987/](https://pubmed.ncbi.nlm.nih.gov/32783987/)  
6. Withania somnifera: from prevention to treatment of cancer \- PMC \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4899165/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4899165/)  
7. Withania somnifera (Indian ginseng) in male infertility: An evidence ..., accessed November 5, 2025, [https://pubmed.ncbi.nlm.nih.gov/30466985/](https://pubmed.ncbi.nlm.nih.gov/30466985/)  
8. Study of Drug Target Identification and Associated Molecular Mechanisms for the Therapeutic Activity and Hair Follicle Induction of Two Ashwagandha Extracts Having Differential Withanolide Constitutions \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10560109/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10560109/)  
9. Pharmacological Insights Into Ashwagandha (Withania somnifera): A Review of Its Immunomodulatory and Neuroprotective Properties \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12423730/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12423730/)  
10. Withaferin A: From Ancient Remedy to Potential Drug Candidate \- PMC \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8705790/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8705790/)  
11. Recent Advancements in Extraction Techniques of Ashwagandha (Withania somnifera) with Insights on Phytochemicals, Structural Significance, Pharmacology, and Current Trends in Food Applications | ACS Omega, accessed November 5, 2025, [https://pubs.acs.org/doi/10.1021/acsomega.3c03491](https://pubs.acs.org/doi/10.1021/acsomega.3c03491)  
12. The effect of Withania somnifera (Ashwagandha) on mental health symptoms in individuals with mental disorders: systematic review and meta-analysis \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12569615/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12569615/)  
13. Pharmacologic overview of Withania somnifera, the Indian Ginseng \- PMC \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11113996/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11113996/)  
14. Effects of Withania somnifera (Ashwagandha) on Stress and the Stress-Related Neuropsychiatric Disorders Anxiety, Depression, and Insomnia \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8762185/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8762185/)  
15. (PDF) An Alternative Treatment for Anxiety: A Systematic Review of Human Trial Results Reported for the Ayurvedic Herb Ashwagandha ( Withania somnifera ) \- ResearchGate, accessed November 5, 2025, [https://www.researchgate.net/publication/268795467\_An\_Alternative\_Treatment\_for\_Anxiety\_A\_Systematic\_Review\_of\_Human\_Trial\_Results\_Reported\_for\_the\_Ayurvedic\_Herb\_Ashwagandha\_Withania\_somnifera](https://www.researchgate.net/publication/268795467_An_Alternative_Treatment_for_Anxiety_A_Systematic_Review_of_Human_Trial_Results_Reported_for_the_Ayurvedic_Herb_Ashwagandha_Withania_somnifera)  
16. Effects of Ashwagandha (Withania somnifera) on Physical Performance: Systematic Review and Bayesian Meta-Analysis \- NIH, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8006238/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8006238/)  
17. Current Prevention of COVID-19: Natural Products and Herbal Medicine \- PMC \- NIH, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7597394/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7597394/)  
18. New botanical guide to help detect adulteration of ashwagandha \- Nutrition Insight, accessed November 5, 2025, [https://www.nutritioninsight.com/news/guidance-document-ashwagandha-root-adulteration-authentication.html](https://www.nutritioninsight.com/news/guidance-document-ashwagandha-root-adulteration-authentication.html)  
19. An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha (Withania somnifera) \- PubMed, accessed November 5, 2025, [https://pubmed.ncbi.nlm.nih.gov/25405876/](https://pubmed.ncbi.nlm.nih.gov/25405876/)  
20. Withania somnifera (Ashwagandha) supplementation: a review of its mechanisms, health benefits, and role in sports performance \- PMC \- NIH, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11800443/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11800443/)  
21. Effects of Withania somnifera on Cortisol Levels in Stressed Human Subjects: A Systematic Review \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10745833/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10745833/)  
22. Biopsychological Effects of Ashwagandha (Withania somnifera) in Athletes and Healthy Individuals: A Systematic Review \- MDPI, accessed November 5, 2025, [https://www.mdpi.com/2813-0413/4/3/24](https://www.mdpi.com/2813-0413/4/3/24)  
23. Effects of Withania somnifera on Cortisol Levels in Stressed Human Subjects: A Systematic Review \- MDPI, accessed November 5, 2025, [https://www.mdpi.com/2072-6643/15/24/5015](https://www.mdpi.com/2072-6643/15/24/5015)  
24. The benefits of ashwagandha (Withania somnifera) supplements on brain function and sports performance \- Frontiers, accessed November 5, 2025, [https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1439294/full](https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1439294/full)  
25. Accurate Education \- Ashwagandha, accessed November 5, 2025, [https://accurateclinic.com/accurate-education-ashwagandha/](https://accurateclinic.com/accurate-education-ashwagandha/)  
26. An updated review on phytochemistry and molecular targets of Withania somnifera (L.) Dunal (Ashwagandha) \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10090468/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10090468/)  
27. Enhancing healthspan with Ashwagandha (Withania somnifera): a comprehensive review of its multifaceted geroprotective benefits \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12417257/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12417257/)  
28. Effects of Ashwagandha (Withania Somnifera) on stress and anxiety ..., accessed November 5, 2025, [https://pubmed.ncbi.nlm.nih.gov/39348746/](https://pubmed.ncbi.nlm.nih.gov/39348746/)  
29. An Alternative Treatment for Anxiety: A Systematic Review of Human Trial Results Reported for the Ayurvedic Herb Ashwagandha (Withania somnifera) \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4270108/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4270108/)  
30. Effect of Ashwagandha (Withania somnifera) extract on sleep: A ..., accessed November 5, 2025, [https://pubmed.ncbi.nlm.nih.gov/34559859/](https://pubmed.ncbi.nlm.nih.gov/34559859/)  
31. Effect of Ashwagandha (Withania somnifera) extract on sleep: A systematic review and meta-analysis \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8462692/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8462692/)  
32. Ashwagandha: Is it helpful for stress, anxiety, or sleep? \- Health Professional Fact Sheet, accessed November 5, 2025, [https://ods.od.nih.gov/factsheets/Ashwagandha-HealthProfessional/](https://ods.od.nih.gov/factsheets/Ashwagandha-HealthProfessional/)  
33. Effects of Ashwagandha (Withania somnifera) on Physical Performance: Systematic Review and Bayesian Meta-Analysis \- PubMed, accessed November 5, 2025, [https://pubmed.ncbi.nlm.nih.gov/33670194/](https://pubmed.ncbi.nlm.nih.gov/33670194/)  
34. Biopsychological Effects of Ashwagandha (Withania somnifera) in Athletes and Healthy Individuals: A Systematic Review \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12372057/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12372057/)  
35. The benefits of ashwagandha (Withania somnifera) supplements on brain function and sports performance \- PMC \- PubMed Central \- NIH, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11327513/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11327513/)  
36. The Effect of Withania Somnifera (Ashwagandha) Supplementation on Maximal Oxygen Uptake and Strength Endurance in Athletes \- ijrpr, accessed November 5, 2025, [https://ijrpr.com/uploads/V6ISSUE9/IJRPR53261.pdf](https://ijrpr.com/uploads/V6ISSUE9/IJRPR53261.pdf)  
37. Effects of Ashwagandha (Withania somnifera) on VO2max: A ... \- NIH, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7230697/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7230697/)  
38. The effect of Ashwagandha (Withania somnifera) on sports ..., accessed November 5, 2025, [https://journalofsportsmedicine.org/full-text/752/eng](https://journalofsportsmedicine.org/full-text/752/eng)  
39. The Effect of Ashwagandha (Withania somnifera) on Sports Performance: A Systematic Review and Meta-Analysis \- ResearchGate, accessed November 5, 2025, [https://www.researchgate.net/publication/391914020\_The\_Effect\_of\_Ashwagandha\_Withania\_somnifera\_on\_Sports\_Performance\_A\_Systematic\_Review\_and\_Meta-Analysis](https://www.researchgate.net/publication/391914020_The_Effect_of_Ashwagandha_Withania_somnifera_on_Sports_Performance_A_Systematic_Review_and_Meta-Analysis)  
40. The Role of Ashwagandha in Exercise Performance and Recovery: An Evidence-Based Review \- ResearchGate, accessed November 5, 2025, [https://www.researchgate.net/publication/393684027\_The\_Role\_of\_Ashwagandha\_in\_Exercise\_Performance\_and\_Recovery\_An\_Evidence-Based\_Review](https://www.researchgate.net/publication/393684027_The_Role_of_Ashwagandha_in_Exercise_Performance_and_Recovery_An_Evidence-Based_Review)  
41. A Systematic Review on Use of Medicinal Plants for Male Infertility Treatment \- PMC, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8520662/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8520662/)  
42. A Randomized, Double-Blind, Placebo-Controlled, Crossover Study Examining the Hormonal and Vitality Effects of Ashwagandha (Withania somnifera) in Aging, Overweight Males \- PMC \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6438434/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6438434/)  
43. Examining the Effects of Herbs on Testosterone Concentrations in ..., accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8166567/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8166567/)  
44. (PDF) A Randomized, Double-Blind, Placebo-Controlled, Crossover Study Examining the Hormonal and Vitality Effects of Ashwagandha \- ResearchGate, accessed November 5, 2025, [https://www.researchgate.net/publication/331645704\_A\_Randomized\_Double-Blind\_Placebo-Controlled\_Crossover\_Study\_Examining\_the\_Hormonal\_and\_Vitality\_Effects\_of\_Ashwagandha](https://www.researchgate.net/publication/331645704_A_Randomized_Double-Blind_Placebo-Controlled_Crossover_Study_Examining_the_Hormonal_and_Vitality_Effects_of_Ashwagandha)  
45. Acute and Repeated Ashwagandha Supplementation Improves Markers of Cognitive Function and Mood \- ResearchGate, accessed November 5, 2025, [https://www.researchgate.net/publication/381281913\_Acute\_and\_Repeated\_Ashwagandha\_Supplementation\_Improves\_Markers\_of\_Cognitive\_Function\_and\_Mood](https://www.researchgate.net/publication/381281913_Acute_and_Repeated_Ashwagandha_Supplementation_Improves_Markers_of_Cognitive_Function_and_Mood)  
46. A systematic review of the clinical use of Withania somnifera (Ashwagandha) to ameliorate cognitive dysfunction | Request PDF \- ResearchGate, accessed November 5, 2025, [https://www.researchgate.net/publication/337370347\_A\_systematic\_review\_of\_the\_clinical\_use\_of\_Withania\_somnifera\_Ashwagandha\_to\_ameliorate\_cognitive\_dysfunction](https://www.researchgate.net/publication/337370347_A_systematic_review_of_the_clinical_use_of_Withania_somnifera_Ashwagandha_to_ameliorate_cognitive_dysfunction)  
47. Dysfunction of the Microbiota-Gut-Brain Axis in Neurodegenerative Disease: The Promise of Therapeutic Modulation With Prebiotics, Medicinal Herbs, Probiotics, and Synbiotics \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7586271/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7586271/)  
48. Neuroprotective Herbs for the Management of Alzheimer's Disease \- MDPI, accessed November 5, 2025, [https://www.mdpi.com/2218-273X/11/4/543](https://www.mdpi.com/2218-273X/11/4/543)  
49. Efficacy and Safety of Ashwagandha Root Extract on Cognitive Functions in Healthy, Stressed Adults: A Randomized, Double-Blind, Placebo-Controlled Study \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8632422/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8632422/)  
50. Effects of Ashwagandha (Withania Somnifera) on Stress and Anxiety: A Systematic Review and Meta-analysis | Request PDF \- ResearchGate, accessed November 5, 2025, [https://www.researchgate.net/publication/384226535\_Effects\_of\_Ashwagandha\_Withania\_Somnifera\_on\_Stress\_and\_Anxiety\_A\_Systematic\_Review\_and\_Meta-analysis](https://www.researchgate.net/publication/384226535_Effects_of_Ashwagandha_Withania_Somnifera_on_Stress_and_Anxiety_A_Systematic_Review_and_Meta-analysis)  
51. Natural Therapies Review 2024 – Western herbal medicine evidence evaluation – Appendix F1 \- Department of Health, Disability and Ageing, accessed November 5, 2025, [https://www.health.gov.au/sites/default/files/2025-04/whm\_appendix\_f1-study\_details\_final.pdf](https://www.health.gov.au/sites/default/files/2025-04/whm_appendix_f1-study_details_final.pdf)  
52. (PDF) The effect of Withania somnifera (Ashwagandha) on mental health symptoms in individuals with mental disorders: systematic review and meta-analysis \- ResearchGate, accessed November 5, 2025, [https://www.researchgate.net/publication/396947709\_The\_effect\_of\_Withania\_somnifera\_Ashwagandha\_on\_mental\_health\_symptoms\_in\_individuals\_with\_mental\_disorders\_systematic\_review\_and\_meta-analysis](https://www.researchgate.net/publication/396947709_The_effect_of_Withania_somnifera_Ashwagandha_on_mental_health_symptoms_in_individuals_with_mental_disorders_systematic_review_and_meta-analysis)  
53. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options \- Frontiers, accessed November 5, 2025, [https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2020.595584/full](https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2020.595584/full)  
54. Liver Dangers of Herbal Products: A Case Report of Ashwagandha-Induced Liver Injury \- PMC \- NIH, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10002162/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10002162/)  
55. Ashwagandha \- LiverTox \- NCBI Bookshelf, accessed November 5, 2025, [https://www.ncbi.nlm.nih.gov/books/NBK548536/](https://www.ncbi.nlm.nih.gov/books/NBK548536/)  
56. Herb-Induced Liver Injury by Ayurvedic Ashwagandha as Assessed for Causality by the Updated RUCAM: An Emerging Cause \- NIH, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10459262/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10459262/)  
57. Ashwagandha-induced liver injury—A case series from India and ..., accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10531359/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10531359/)  
58. Ashwagandha-Induced Hepatic Injury: A Case Report \- PMC \- NIH, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11564894/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11564894/)  
59. A double-blind, randomized, placebo-controlled trial on the effect of Ashwagandha (Withania somnifera Dunal.) root extract in improving cardiorespiratory endurance and recovery in healthy athletic adults \- ResearchGate, accessed November 5, 2025, [https://www.researchgate.net/publication/349342354\_A\_double-blind\_randomized\_placebo-controlled\_trial\_on\_the\_effect\_of\_Ashwagandha\_Withania\_somnifera\_Dunal\_root\_extract\_in\_improving\_cardiorespiratory\_endurance\_and\_recovery\_in\_healthy\_athletic\_adults](https://www.researchgate.net/publication/349342354_A_double-blind_randomized_placebo-controlled_trial_on_the_effect_of_Ashwagandha_Withania_somnifera_Dunal_root_extract_in_improving_cardiorespiratory_endurance_and_recovery_in_healthy_athletic_adults)  
60. Ashwagandha as a Unique Cause of Thyrotoxicosis Presenting With Supraventricular Tachycardia \- Semantic Scholar, accessed November 5, 2025, [https://www.semanticscholar.org/paper/Ashwagandha-as-a-Unique-Cause-of-Thyrotoxicosis-Kamal-Patel/43442783d8b2551bad0ca1440642185147a3693d](https://www.semanticscholar.org/paper/Ashwagandha-as-a-Unique-Cause-of-Thyrotoxicosis-Kamal-Patel/43442783d8b2551bad0ca1440642185147a3693d)  
61. Achievements in Hypothyroidism Treatment with Herbal Medicine: A Systematic Review of Randomized Controlled Trials | Request PDF \- ResearchGate, accessed November 5, 2025, [https://www.researchgate.net/publication/369773823\_Achievements\_in\_Hypothyroidism\_Treatment\_with\_Herbal\_Medicine\_A\_Systematic\_Review\_of\_Randomized\_Controlled\_Trials](https://www.researchgate.net/publication/369773823_Achievements_in_Hypothyroidism_Treatment_with_Herbal_Medicine_A_Systematic_Review_of_Randomized_Controlled_Trials)  
62. Chirpycharm REVIEWS 2025 (Not What I Expected) My Honest, accessed November 5, 2025, [https://content-calpoly-edu.s3.amazonaws.com/advising/1/webform/Chirpycharmreconstruction\_SGGw.pdf](https://content-calpoly-edu.s3.amazonaws.com/advising/1/webform/Chirpycharmreconstruction_SGGw.pdf)  
63. (PDF) Botanical Medicine for Thyroid Regulation \- ResearchGate, accessed November 5, 2025, [https://www.researchgate.net/publication/244889874\_Botanical\_Medicine\_for\_Thyroid\_Regulation](https://www.researchgate.net/publication/244889874_Botanical_Medicine_for_Thyroid_Regulation)  
64. Painless Thyroiditis by Withania somnifera (Ashwagandha) \- PMC \- NIH, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10981964/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10981964/)  
65. Can Ashwagandha Benefit the Endocrine System?—A Review \- MDPI, accessed November 5, 2025, [https://www.mdpi.com/1422-0067/24/22/16513](https://www.mdpi.com/1422-0067/24/22/16513)  
66. Ashwagandha as a Unique Cause of Thyrotoxicosis Presenting With Supraventricular Tachycardia \- PMC \- NIH, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9035336/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9035336/)  
67. Safety of Ashwagandha \- Ministry of Ayush, accessed November 5, 2025, [https://ayush.gov.in/images/domains/quality\_standards/safetyReportAshwagandha.pdf](https://ayush.gov.in/images/domains/quality_standards/safetyReportAshwagandha.pdf)  
68. Quantifying Withanolides in Plasma: Pharmacokinetic Studies and Analytical Methods, accessed November 5, 2025, [https://www.mdpi.com/2072-6643/16/22/3836/review\_report](https://www.mdpi.com/2072-6643/16/22/3836/review_report)  
69. Withania somnifera (L.) Dunal (Ashwagandha): A comprehensive review on ethnopharmacology, pharmacotherapeutics, biomedicinal and toxicological aspects \- PubMed, accessed November 5, 2025, [https://pubmed.ncbi.nlm.nih.gov/34649336/](https://pubmed.ncbi.nlm.nih.gov/34649336/)  
70. Pharmacokinetics and bioequivalence of Withania somnifera (Ashwagandha) extracts – A double blind, crossover study in healthy adults \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10746415/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10746415/)  
71. Superior Bioavailability of a Novel 1.5% Ashwagandha Formulation (Zenroot™): A Randomized, Double-Blind, Single-Dose, Comparative, Oral Bioavailability Study in Healthy Adults \- PMC \- NIH, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12474700/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12474700/)  
72. Quantifying Withanolides in Plasma: Pharmacokinetic Studies and ..., accessed November 5, 2025, [https://www.mdpi.com/2072-6643/16/22/3836](https://www.mdpi.com/2072-6643/16/22/3836)  
73. Harder, better, faster, stronger? Retrospective chart review of adverse events of interactions between adaptogens and antidepressant drugs \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10565488/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10565488/)  
74. Artificial Intelligence Models and Tools for the Assessment of Drug–Herb Interactions \- MDPI, accessed November 5, 2025, [https://www.mdpi.com/1424-8247/18/3/282](https://www.mdpi.com/1424-8247/18/3/282)  
75. Effect of Botanical Immunomodulators on Human CYP3A4 Inhibition \- ResearchGate, accessed November 5, 2025, [https://www.researchgate.net/publication/257534919\_Effect\_of\_Botanical\_Immunomodulators\_on\_Human\_CYP3A4\_Inhibition](https://www.researchgate.net/publication/257534919_Effect_of_Botanical_Immunomodulators_on_Human_CYP3A4_Inhibition)  
76. In vitro effect of Withania somnifera, AYUSH-64, and remdesivir on the activity of CYP-450 enzymes: Implications for possible herb−drug interactions in the management of COVID-19 \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9597875/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9597875/)  
77. Ashwagandha (Withania somnifera) Plant Extracts Affect the Cytochrome P450 System and Cytotoxicity of Primary Human Hepatocytes | Request PDF \- ResearchGate, accessed November 5, 2025, [https://www.researchgate.net/publication/392968695\_Ashwagandha\_Withania\_somnifera\_Plant\_Extracts\_Affect\_the\_Cytochrome\_P450\_System\_and\_Cytotoxicity\_of\_Primary\_Human\_Hepatocytes](https://www.researchgate.net/publication/392968695_Ashwagandha_Withania_somnifera_Plant_Extracts_Affect_the_Cytochrome_P450_System_and_Cytotoxicity_of_Primary_Human_Hepatocytes)  
78. Abacavir \- HEP Drug Interactions, accessed November 5, 2025, [https://www.hep-druginteractions.org/interactions/1209/all](https://www.hep-druginteractions.org/interactions/1209/all)  
79. Pharmacoepidemiological Data on Drug–Herb Interactions: Serotonin Syndrome, Arrhythmias and the Emerging Role of Artificial Intelligence \- MDPI, accessed November 5, 2025, [https://www.mdpi.com/2813-0618/4/4/22](https://www.mdpi.com/2813-0618/4/4/22)  
80. Safety, toxicity and pharmacokinetic assessment of oral Withaferin-A in mice \- PMC \- NIH, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9742883/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9742883/)  
81. Harder, better, faster, stronger? Retrospective chart review of adverse events of interactions between adaptogens and antidepressant drugs \- Frontiers, accessed November 5, 2025, [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1271776/full](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1271776/full)  
82. Ashwagandha and Its Role in Stress Reduction, Hormonal Balance, and Athletic Recovery \- UMK, accessed November 5, 2025, [https://apcz.umk.pl/JEHS/article/download/61874/43309/200351](https://apcz.umk.pl/JEHS/article/download/61874/43309/200351)  
83. Safety and efficacy of Withania somnifera for anxiety and insomnia: Systematic review and meta-analysis | Request PDF \- ResearchGate, accessed November 5, 2025, [https://www.researchgate.net/publication/382740264\_Safety\_and\_efficacy\_of\_Withania\_somnifera\_for\_anxiety\_and\_insomnia\_Systematic\_review\_and\_meta-analysis](https://www.researchgate.net/publication/382740264_Safety_and_efficacy_of_Withania_somnifera_for_anxiety_and_insomnia_Systematic_review_and_meta-analysis)  
84. Ashwagandha benefits \- Fitness World Nutrition, accessed November 5, 2025, [https://www.fitness-world-nutrition.com/en/blogs/news/ashwagandha-bienfaits](https://www.fitness-world-nutrition.com/en/blogs/news/ashwagandha-bienfaits)  
85. Efficacy of Ashwagandha Extract Formulation (ASVAMAN®) on Improvement of Energy and Endurance: A Randomized, Double-blind, Placebo-controlled Clinical Study in Healthy Adults | European Journal of Medical and Health Sciences, accessed November 5, 2025, [https://www.ej-med.org/index.php/ejmed/article/view/2304/2003](https://www.ej-med.org/index.php/ejmed/article/view/2304/2003)  
86. HPLC Analysis of Ashwagandha Supplements Using Alliance™ iS, accessed November 5, 2025, [https://www.waters.com/content/dam/waters/en/app-notes/2024/720008317/720008317-ko.pdf](https://www.waters.com/content/dam/waters/en/app-notes/2024/720008317/720008317-ko.pdf)  
87. Pharmacokinetic Study of Withanosides and Withanolides from Withania somnifera Using Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry (UHPLC-MS/MS) \- NIH, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8912008/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8912008/)  
88. Investigating 11 Withanosides and Withanolides by UHPLC–PDA and Mass Fragmentation Studies from Ashwagandha (Withania somnifera) | ACS Omega \- ACS Publications, accessed November 5, 2025, [https://pubs.acs.org/doi/10.1021/acsomega.0c03266](https://pubs.acs.org/doi/10.1021/acsomega.0c03266)  
89. A multi-detector analytical approach for characterizing complex botanical extracts: a case study on ashwagandha \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12367915/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12367915/)  
90. Botanical Ingredient Forensics: Detection of Attempts to Deceive Commonly Used Analytical Methods for Authenticating Herbal Dietary and Food Ingredients and Supplements | Journal of Natural Products \- ACS Publications, accessed November 5, 2025, [https://pubs.acs.org/doi/10.1021/acs.jnatprod.2c00929](https://pubs.acs.org/doi/10.1021/acs.jnatprod.2c00929)  
91. A feasible procedure to detect widespread wrong labeling of Ashwagandha root extracts in dietary supplements, accessed November 5, 2025, [https://www.explorationpub.com/uploads/Article/A101046/101046.pdf](https://www.explorationpub.com/uploads/Article/A101046/101046.pdf)  
92. ABC-AHP-NCNPR Botanical Adulterants Prevention Program Publishes Ashwagandha Root and Root Extract Bulletin \- GlobeNewswire, accessed November 5, 2025, [https://www.globenewswire.com/news-release/2019/01/15/1692564/0/en/ABC-AHP-NCNPR-Botanical-Adulterants-Prevention-Program-Publishes-Ashwagandha-Root-and-Root-Extract-Bulletin.html](https://www.globenewswire.com/news-release/2019/01/15/1692564/0/en/ABC-AHP-NCNPR-Botanical-Adulterants-Prevention-Program-Publishes-Ashwagandha-Root-and-Root-Extract-Bulletin.html)  
93. American Botanical Council, accessed November 5, 2025, [https://www.herbalgram.org/](https://www.herbalgram.org/)  
94. Botanical Ingredient Forensics: Detection of Attempts to Deceive Commonly Used Analytical Methods for Authenticating Herbal Dietary and Food Ingredients and Supplements \- PMC \- NIH, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9972475/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9972475/)  
95. A feasible procedure to detect widespread wrong labeling of ..., accessed November 5, 2025, [https://www.explorationpub.com/Journals/eff/Article/101046](https://www.explorationpub.com/Journals/eff/Article/101046)  
96. Latest Information About Sexual Enhancers \- ConsumerLab.com, accessed November 5, 2025, [https://www.consumerlab.com/sexual-enhancers/](https://www.consumerlab.com/sexual-enhancers/)  
97. Heavy Metal Contamination in Adaptogenic Herbal Dietary Supplements: Experimental, Assessment and Regulatory Safety Perspectives \- MDPI, accessed November 5, 2025, [https://www.mdpi.com/2079-7737/14/11/1479](https://www.mdpi.com/2079-7737/14/11/1479)  
98. (PDF) Chemical, microbial and safety profiling of a standardized Withania somnifera (Ashwagandha) extract and Withaferin A, a potent novel phytotherapeutic of the millennium \- ResearchGate, accessed November 5, 2025, [https://www.researchgate.net/publication/368766260\_Chemical\_microbial\_and\_safety\_profiling\_of\_a\_standardized\_Withania\_somnifera\_Ashwagandha\_extract\_and\_Withaferin\_A\_a\_potent\_novel\_phytotherapeutic\_of\_the\_millennium](https://www.researchgate.net/publication/368766260_Chemical_microbial_and_safety_profiling_of_a_standardized_Withania_somnifera_Ashwagandha_extract_and_Withaferin_A_a_potent_novel_phytotherapeutic_of_the_millennium)  
99. Mutagenicity and safety evaluation of Ashwagandha (Withania somnifera) root aqueous extract in different models \- NIH, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10787217/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10787217/)  
100. Regulatory Requirement Sufficiency for Registration of Traditional Herbal Medicine Based Products in Association of Southeast Asian Nations Regions: A Model Study with Ashwagandha Tablets, accessed November 5, 2025, [https://www.ijpsonline.com/articles/regulatory-requirement-sufficiency-for-registration-of-traditional-herbal-medicine-based-products-in-association-of-southeast-asia-4579.html](https://www.ijpsonline.com/articles/regulatory-requirement-sufficiency-for-registration-of-traditional-herbal-medicine-based-products-in-association-of-southeast-asia-4579.html)  
101. DNA Barcoding of Ayurvedic Herbal Supplements used for the Purported Treatment of COVID-19 \- Chapman University Digital Commons, accessed November 5, 2025, [https://digitalcommons.chapman.edu/cgi/viewcontent.cgi?article=1028\&context=food\_science\_theses](https://digitalcommons.chapman.edu/cgi/viewcontent.cgi?article=1028&context=food_science_theses)  
102. Adulteration of selected dietary supplements and their detection methods \- ResearchGate, accessed November 5, 2025, [https://www.researchgate.net/publication/340781390\_Adulteration\_of\_selected\_dietary\_supplements\_and\_their\_detection\_methods](https://www.researchgate.net/publication/340781390_Adulteration_of_selected_dietary_supplements_and_their_detection_methods)  
103. A validated green UPLC method for the quantification of ... \- Bohrium, accessed November 5, 2025, [https://www.bohrium.com/paper-details/a-validated-green-uplc-method-for-the-quantification-of-synthetic-pharmaceutical-adulterants-in-the-extract-of-the-aphrodisiac-herbal-plant-ashwagandha-withania-somnifera-and-in-spiked-human-plasma/949107256576704675-3486](https://www.bohrium.com/paper-details/a-validated-green-uplc-method-for-the-quantification-of-synthetic-pharmaceutical-adulterants-in-the-extract-of-the-aphrodisiac-herbal-plant-ashwagandha-withania-somnifera-and-in-spiked-human-plasma/949107256576704675-3486)  
104. Sexual Enhancement Supplements Reviewed by ConsumerLab.com, accessed November 5, 2025, [https://www.consumerlab.com/sexual-enhancement/](https://www.consumerlab.com/sexual-enhancement/)  
105. Herbal supplements and evidence-based recommendations | Dietitians On Demand Blog, accessed November 5, 2025, [https://dietitiansondemand.com/herbal-supplements-and-evidence-based-recommendations/](https://dietitiansondemand.com/herbal-supplements-and-evidence-based-recommendations/)